Investigation of the Impact of Foretinib on AURKA and AURKB Expression in T98 Glioblastoma Cell Line


Background: Gliomas are a common type of the primary brain tumors and account formore than 40% of all central nervous system (CNS) tumors. Glioblastoma (GBM) remainsone of the most fatal human malignancies as it is highly angiogenic. Foretinib is anoral multikinase inhibitor that has been shown to exhibit antitumor activity in previousclinical studies. AURKA and AURKB have been shown to be overexpressed in variouscancers.The purpose of this study was to investigate the effect of foretinib on the expressionof AURKA and AURKB in the T98 cell line.Materials and Methods: In this study, the T98 cell line was selected as an experimentalmodel of glioblastoma. The cultured cells were exposed to different concentrationsof foretinib (5 μM, 10 μM, 20 μM, and 0 μM as control). Following that, we examinedthe changes in the expression of AURKA and AURKB under the influence of foretinibcompared to control using quantitative real-time polymerase chain reaction (qRT-PCR).Results: The expression of AURKA and AURKB were found to be significantly reducedin the foretinib treated group compared to the control. The results demonstrated thatincreasing the concentration of foretinib led to reduction in the expression of both thegenes.Conclusion: These findings indicate that the foretinib can decrease the mRNA levelsof AURKA and AURKB. Thus, we suggest that foretinib may be an effective drug forGBM treatment and can be considered for future studies.